


IN THE CLAIMS

Claims 1-37 (cancelled)

38 (currently amended): A method for inhibiting bone metastases in a patient having prostate cancer which comprises administering to the patient ~~in need thereof~~ a therapeutically effective amount of a compound of formula III



III,

or a pharmaceutically acceptable salt thereof.

39 (original): The method of Claim 38 wherein the bone metastases are osteoblastic.

Claims 40-41 (cancelled)

42 (currently amended): The method of Claim 40 which additionally comprises ~~the administration of~~ administering an anticancer drug.

43 (currently amended): The method of Claim 42 wherein the ~~additional~~ anticancer drug is selected from the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide,

vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.


44 (currently amended): The method of Claim 40 which additionally comprises ~~the administration of~~ administering radiation ~~therapy~~.

45 (currently amended): The method of Claim 40 which additionally comprises ~~the administration of~~ administering at least one therapeutic agent which impedes net bone loss.

46 (currently amended): The method of Claim 45 wherein the therapeutic agent is a bisphosphonate.

47-55 (cancelled)

56 (currently amended): A method for preventing new bone metastases in a patient having prostate cancer which comprises ~~administering~~ administering to the patient ~~in need thereof~~ a therapeutically effective amount of ~~an endothelin ET-A receptor antagonist~~ a compound of formula III



III,

or a pharmaceutically acceptable salt thereof.

Claims 57-58 (cancelled)

59 (new): The method of Claim 56 wherein the bone metastases are osteoblastic.

60 (new): The method of Claim 56 which additionally comprises administering an anticancer drug.


61 (new): The method of Claim 60 wherein the anticancer drug is selected from the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

62 (new): The method of Claim 56 which additionally comprises administering radiation.

63 (new): The method of Claim 56 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.

64 (new): The method of Claim 63 wherein the therapeutic agent is a bisphosphonate.

65 (new): A method for inhibiting metastatic growth in a patient having prostate cancer which comprises administering to the patient a therapeutically effective amount of a compound of formula III



III,

or a pharmaceutically acceptable salt thereof.

66 (new): The method of Claim 65 wherein the bone metastases are osteoblastic.

67 (new): The method of Claim 65 which additionally comprises administering an anticancer drug.

68 (new): The method of Claim 67 wherein the anticancer drug is selected from the group consisting of leuprolide, goserelin, bicalutamide, nilutamide, flutamide, vitamin D, vitamin D analogues, estrogen, estrogen analogues, prednisone, hydrocortisone, ketoconazole, cyproterone acetate, and progesterone.

69 (new): The method of Claim 65 which additionally comprises administering radiation.

70 (new): The method of Claim 65 which additionally comprises administering at least one therapeutic agent which impedes net bone loss.

71 (new): The method of Claim 70 wherein the therapeutic agent is a bisphosphonate.